

Resource Summary Report

Generated by PRECISE-TBI on Aug 9, 2026

Pacific Blue(TM) anti-human CD3

RRID:AB_10552893

Type: Antibody

Proper Citation

BioLegend Cat# 300329, RRID:AB_10552893

Antibody Information

URL: http://antibodyregistry.org/AB_10552893

Proper Citation: BioLegend Cat# 300329, RRID:AB_10552893

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Pacific Blue(TM) anti-human CD3

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: Clone HIT3a

Antibody ID: AB_10552893

Vendor: BioLegend

Catalog Number: 300329

Alternative Catalog Numbers: 300330

Record Creation Time: 20250820T010943+0000

Record Last Update: 20250820T101145+0000

Ratings and Alerts

No rating or validation information has been found for Pacific Blue(TM) anti-human CD3.

No alerts have been found for Pacific Blue(TM) anti-human CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 9 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Li YR, et al. (2026) Protocol to generate human stem cell-derived CD70-directed allogeneic CAR-NKT cells for treating renal cell carcinoma. STAR protocols, 7(1), 104340.

Lyu Z, et al. (2025) Protocol for assessing pharmacokinetics and pharmacodynamics of human CAR-NKT cells in humanized mouse models using bioluminescence imaging. STAR protocols, 6(3), 103957.

Li YR, et al. (2025) Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells. Med (New York, N.Y.), 100804.

Schwarz E, et al. (2025) Trabectedin Enhances the Antitumor Effects of IL-12 in Triple-Negative Breast Cancer. Cancer immunology research, 13(4), 560.

Li YR, et al. (2025) Multimodal targeting of metastatic renal cell carcinoma via CD70-directed allogeneic CAR-NKT cells. Cell reports. Medicine, 6(9), 102321.

Lin F, et al. (2024) Multimodal targeting chimeras enable integrated immunotherapy leveraging tumor-immune microenvironment. Cell, 187(26), 7470.

Zhang X, et al. (2024) Miltefosine reinvigorates exhausted T_H1 cells by targeting their bioenergetic state. Cell reports. Medicine, 5(12), 101869.

Zhang X, et al. (2022) Depletion of BATF in CAR-T cells enhances antitumor activity by inducing resistance against exhaustion and formation of central memory cells. Cancer cell, 40(11), 1407.

Roerden M, et al. (2021) Impact of Mantle Cell Lymphoma Contamination of Autologous Stem Cell Grafts on Outcome after High-Dose Chemotherapy. Cancers, 13(11).